IGF::OT::IGF : Purity Specifications, Storage and Distribution for Medications Development. July 9, 2012 - July 8, 2017. PURPOSE: To fix a typographical error in Modification 14.

自1992年以来，NIDA一直保持着一份多样化的化合物清单，同时努力将这些化合物分配到NIDA指定的测试地点。所有化合物的纯度都受到监控，以确保稳定性。所有化合物的机密性是通过为每个化合物分配一个唯一的标识符来维护的，从而使化合物对测试地点变得盲目。许多化合物将被储存起来，以支持临床前研究。由于其中一些化合物可以根据《受控物质法》列入清单，因此根据DEA法规(联邦法规(CFR)第21章第1300部分)维持广泛的库存和运输跟踪系统是至关重要的。

Since 1992, NIDA has maintained a diverse inventory of compounds with a simultaneous effort directed at the distribution of these compounds to NIDA specified testing sites. The purity of all compounds is monitored to assure stability. The confidentiality of all compounds is maintained by assigning each compound a unique identifier, thereby blinding the compound to the test sites. Many of the compounds will be stocked to support preclinical studies. Since some of these compounds could be scheduled under the Controlled Substances Act, it is essential that an extensive inventory and shipment tracking system be maintained according to DEA Regulations (Code of Federal Regulations (CFR) Title 21 Part 1300).